

Table S3: Summary details of included RCTs (n = 9)

Citation & Country	Study type	Influenza type & transmission	Intervention	Duration of intervention	Comparator	Outcome measure	Results
Hayden et al. 1999 USA	RCT	Seasonal (Individual) A(H1N1)	Osetamivir 100mg oral	5 days	Placebo	PE	100% PE for individual against laboratory confirmed influenza (p<0.001) 61% PE for individual against serology confirmed influenza (p=0.16)
Hayden et al. 1999 USA	RCT	Seasonal (Individual) A(H1N1), A(H3N2) & B	Osetamivir 75mg oral	42 days	Placebo	PE	87% (95% CI 65-96%) PE for individual against laboratory confirmed influenza (p<0.001) 74% (95% CI 53-88%) PE for individual against influenza-like illness (p<0.001)
Monto et al. 1999 USA	RCT	Seasonal (Individual) A(H3N2)	Zanamivir 10mg inhaled	28 days	Placebo	PE	67% (95% CI 39-83%) PE for individual against laboratory confirmed influenza (p<0.001) 84% (95% CI 55-94%) PE for individual against laboratory confirmed influenza with fever (p<0.001)
Kaiser et al. 2000 North America & Europe	RCT	Seasonal (Household-type) A(H3N2)	Zanamivir 10 mg inhaled & 16mg/ml intranasal sprays	5 days	Placebo	PE	73% PE for individual against laboratory confirmed influenza (p=0.058)
Hayden et al. 2000 USA, Canada, UK & Finland	RCT	Seasonal (Household) A(H3N2) & B	Zanamivir 10mg inhaled	10 days	Placebo	PE	72% (95% CI 42-87%) PE for household against laboratory confirmed influenza (p<0.001)

Welliver et al. 2001	RCT	Seasonal (Household)	Oseltamivir 75mg oral	7 days	Placebo	PE	89% (95% CI 67-97%) PE for individual against laboratory confirmed influenza (p<0.001)
North America & Europe		A(H3N2) & B					84% (95% CI 49-95%) PE for household against laboratory confirmed influenza (p<0.001)
Monto et al. 2002	RCT	Seasonal (Household)	Zanamivir 10mg inhaled	10 days	Placebo	PE	81% (95% CI 64-90%) PE for household against laboratory confirmed influenza (p<0.001)
North America, Europe, Australia, New Zealand & S/Africa		A(H1N1), A(H3N2) & B					82% PE for individual against laboratory confirmed influenza (p value not provided)
Hayden et al. 2004	RCT	Seasonal (Household)	Oseltamivir 75mg oral	10 days (prophylaxis)	Treatment alone	PE	58.5% (95% CI 15.6-79.6%) PE for household against laboratory confirmed influenza (p =0.0114)
North America & Europe		A(H1N1) & B		5days (treatment of case)			68% (95% CI 34.9-84.2%) PE for individual against laboratory confirmed influenza (p = 0.0017)
LaForce et al. 2007	RCT	Seasonal (Individual)	Zanamivir 10mg inhaled	28 days	Placebo	PE	83% PE for individual against laboratory confirmed influenza (p<0.001)
USA, Canada, Czech Republic, France, Latvia & Germany		A(H1N1), A(H3N2) & B					